- Home
- IFRX vs RPTX Comparison
IFRX vs RPTX Comparison
Compare IFRX & RPTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | IFRX | RPTX |
|---|---|---|
| Founded | 2007 | 2016 |
| Country | Germany | Canada |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 81.3M | 92.4M |
| IPO Year | 2017 | 2020 |
Fundamental Metrics
Financial Performance| Metric | IFRX | RPTX |
|---|---|---|
| Price | $1.02 | $2.59 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 6 | 1 |
| Target Price | ★ $8.50 | $3.00 |
| AVG Volume (30 Days) | 656.0K | ★ 1.5M |
| Earning Date | 11-10-2025 | 03-02-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | $73,729.00 | ★ $11,870,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $1,054.36 | $3,233.33 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $0.71 | $0.89 |
| 52 Week High | $2.77 | $2.66 |
Technical Indicators
Market Signals| Indicator | IFRX | RPTX |
|---|---|---|
| Relative Strength Index (RSI) | 43.09 | 70.80 |
| Support Level | $0.99 | $2.52 |
| Resistance Level | $1.16 | $2.66 |
| Average True Range (ATR) | 0.08 | 0.05 |
| MACD | 0.00 | -0.00 |
| Stochastic Oscillator | 13.04 | 84.85 |
Price Performance
Historical ComparisonAbout IFRX InflaRx N.V.
InflaRx NV is a clinical-stage biopharmaceutical company focused on applying proprietary anti-C5a/C5aR technology to discover and develop first-in-class, potent, and specific inhibitors of the complement activation factor known as C5a and its receptor known as C5aR. C5a is an inflammatory mediator involved in the progression of a wide variety of autoimmune and other inflammatory diseases. Its product candidate, vilobelimab, is a novel intravenously delivered first-in-class anti-C5a monoclonal antibody that selectively binds to free C5a and has demonstrated disease-modifying clinical activity and tolerability in multiple clinical settings.
About RPTX Repare Therapeutics Inc.
Repare Therapeutics Inc is a precision medicine oncology company focused on the development of synthetic lethality-based therapies for patients with cancer. The Company's focus is the research, development and commercialization of precision oncology drugs targeting specific vulnerabilities of tumors in genetically defined patient populations.